Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival

Clinical Cancer Research

Volumn 20, Issue 19, 2014, Pages 5124-5132

  Dabir, Snehal ^a   Kluge, Amy ^a   Kresak, Adam ^a   Yang, Michael ^a   Fu, Pingfu ^a   Groner, Bernd ^b   Wildey, Gary ^a   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Institute for Biomedical Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; PROTEIN PIAS3; REGULATOR PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; CHAPERONE; MESSENGER RNA; PEPTIDE FRAGMENT; PIAS3 PROTEIN, HUMAN; PROTEIN INHIBITOR OF ACTIVATED STAT;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENETIC DATABASE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT MESOTHELIOMA; OVERALL SURVIVAL; PIAS3 GENE; PREDICTION; PROBABILITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENETICS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MORTALITY; PROGNOSIS; RNA INTERFERENCE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR CHAPERONES; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN INHIBITORS OF ACTIVATED STAT; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 84908287331     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1233     Document Type: Article

References (40)

1. Groner B. Molecular and cellular endocrinology: special issue on cytokine signaling. Mol Cell Endocrinol 2014;382:551.
2. Groner B. Determinants of the extent and duration of STAT3 signaling. JAKSTAT 2012;1:211-5.
3. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
4. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-42.
5. Borghouts C, Delis N, Brill B, Weiss A, Mack L, Lucks P, et al. A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells. JAKSTAT 2012;1:44-54.
6. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.
7. Sharrocks AD. PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases? Genes Dev 2006;20:754-8.
8. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 2006;16:196-202.
9. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278:1803-5.
10. Dabir S, Kluge A, Dowlati A. The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. Mol Cancer Res 2009;7:1854-60.
11. Kluge A, Dabir S, Kern J, Nethery D, Halmos B, Ma P, et al. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer 2009;125:1728-34.
12. Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, et al. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 2006;8:817-25.
13. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, et al. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 2008;14:4694-704.
14. Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R, Dowlati A. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol 2011;5:256-64.
15. Dabir S, Kluge A, Aziz MA, Houghton JA, Dowlati A. Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors. Cancer Biol Ther 2011;12:139-51.
16. Unkila M, McColl KS, Thomenius MJ, Heiskanen K, Distelhorst CW. Unreliability of the cytochrome c-enhanced green fluorescent fusion protein as a marker of cytochrome c release in cells that overexpress Bcl-2. J Biol Chem 2001;276:39132-7.
17. Borghouts C, Tittmann H, Delis N, Kirchenbauer M, Brill B, Groner B. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death. Mol Cancer Res 2010;8:539-53.
18. Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B-Stat Methodol 1972;34:187-220.
19. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
20. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002;62:4963-7.
21. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 1958;53:457-81.
22. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005;41:1955-68.
23. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008;269:199-225.
24. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 2010;110:447-56.
25. Achcar Rde O, Cagle PT, Jagirdar J. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch Pathol Lab Med 2007;131:1350-60.
26. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
27. Jakobsen JN, Sorensen JB. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol 2011;68:1-15.
28. Pasello G, Favaretto A. Molecular targets in malignant pleural mesothelioma treatment. Curr Drug Targets 2009;10:1235-44.
29. Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT, Testa JR. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 2010;1:493-505.
30. Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia 2011;13:12-22.
31. Govindan R, Kratzke RA, Herndon JE II, Niehans GA, Vollmer R, Watson D, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11:2300-4.
32. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-13.
33. Zhang X, Yue P, Page BDG, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012;109:9623-8.
34. Li H, Gao H, Bijukchhe SM, Wang Y, Li T. PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer. Med Hypotheses 2013;81:1151-4.
35. Liu LM, Yan MG, Yang DH, Sun WW, Zhang JX. The expression of protein inhibitor of activated signal transducers and activators of transcription 3 in the evolutionary process of gastric cancer. Eur J Intern Med 2011;22:e31-5.
36. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18.
37. Rocks N, Bekaert S, Coia I, Paulissen G, Gueders M, Evrard B, et al. Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer 2012;107:1083-92.
38. Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol Cancer Res 2008;6:267-81.
39. Li L, Zhao YL, Wang H, Li YJ, Xu X, Liu Q. Base-catalyzed bicyclization of dialkyl glutaconates with cinnamoylacetamides: a synthetic strategy for isoquinolinedione derivatives. Chem Commun 2014;50:6458-60.
40. Groner B, Weiss A. Targeting survivin in cancer: novel drug development approaches. Biodrugs 2014;28:27-39.